60 Degrees Pharmaceuticals Introduces ARAKODA® 8-Count Format
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW), a leader in the pharmaceutical industry focused on developing innovative medicines for infectious diseases, is excited to announce the launch of ARAKODA® (tafenoquine) in a new 8-count bottle format. This new packaging aims to enhance convenience for patients traveling to malaria-endemic regions.
Convenient Dental Health for Travelers
The 8-count bottle format of ARAKODA® is now accessible through major retail pharmacies. This particular option is designed for individuals engaging in short-term trips—specifically those under one week—to areas where malaria is prevalent. As a unique weekly prophylactic treatment, ARAKODA® covers both the liver and blood stages of malaria, providing comprehensive protection.
Understanding ARAKODA® and Its Benefits
ARAKODA® offers a powerful solution for malaria prevention. It is approved for individuals aged 18 and older and stands out as the only therapeutic option administered weekly that protects against all malaria stages. This is especially beneficial for travelers, ensuring they can enjoy their journey with peace of mind regarding malaria risks.
What is Tafenoquine?
Tafenoquine, the active ingredient in ARAKODA®, was initially discovered by the Walter Reed Army Institute of Research. It received approval for malaria prophylaxis in the United States and has also been launched in Australia. Tafenoquine provides a long terminal half-life of approximately 16 days, allowing for less frequent dosing compared to traditional malaria treatments, significantly easing the burden on users.
Prescription and Administration of ARAKODA®
For those at risk of malaria, healthcare providers recommend ARAKODA® at a dosage of two 100 mg tablets once daily for three days before traveling to endemic areas. During their stay, travelers should take two 100 mg tablets every week, then another two tablets within a week after leaving the area. It’s crucial that both patients and their prescribers are aware of important safety information regarding ARAKODA®, ensuring a thorough understanding of the medication.
Safety & Contraindications
While ARAKODA® is effective, certain contraindications must be considered. Patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency or those presenting unknown G6PD status should avoid this medication. Moreover, it is not recommended for lactating women if their infants are G6PD deficient or have an undisclosed status. Others who should not use ARAKODA® include individuals with a history of mental health disorders or hypersensitivity to tafenoquine.
Understanding Risks and Monitoring
Potential side effects include hemolytic anemia, particularly relevant for individuals with G6PD deficiency. Therefore, G6PD testing prior to prescribing ARAKODA® is crucial. Patients must be monitored for signs of hemolysis, and those experiencing psychotic symptoms should seek mental health evaluations. This ensures the safety and well-being of all users.
Common Side Effects and Interactions
Common side effects can include headaches, dizziness, and gastrointestinal disturbances such as nausea and diarrhea. Additionally, healthcare providers should be aware of potential drug interactions, specifically with medications that are affected by organic cation transporter systems.
About 60 Degrees Pharmaceuticals, Inc.
Founded in 2010, 60 Degrees Pharmaceuticals, Inc. is committed to developing and marketing new pharmaceuticals aimed at combating infectious diseases. The company has seen success with ARAKODA®, which was FDA approved in 2018 for malaria prevention. The company continues to collaborate with esteemed research organizations to ensure ongoing innovation and success in treating infectious diseases worldwide.
The headquarters of 60 Degrees Pharmaceuticals is based in Washington, D.C., and they have a majority-owned subsidiary located in Australia. For further information, interested parties are encouraged to explore the company's resources online.
Frequently Asked Questions
What is ARAKODA® used for?
ARAKODA® is primarily used for the prophylaxis of malaria in adults traveling to endemic areas.
How is ARAKODA® administered?
Patients take two 100 mg tablets daily for three days prior to travel, followed by two tablets weekly during their trip and two after returning.
What are the common side effects of ARAKODA®?
Common side effects include headaches, dizziness, nausea, and gastrointestinal disturbances.
Who should avoid using ARAKODA®?
Individuals with G6PD deficiency, a history of mental health disorders, or hypersensitivity to tafenoquine should not use ARAKODA®.
How long is tafenoquine effective?
Tafenoquine has a long half-life of about 16 days, leading to less frequent dosing for malaria prophylaxis.
